Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: gamesmistress who wrote (212)	2/5/1999 11:11:00 AM
From: Phil Cressman	Read Replies (1) \| Respond to of 5582

Nicotine! With all the excitement about colds it seems that investors have completely forgotten that next week marks the start of competition in the nicotine chewing gum market! Gumm will certainly profit from this market either through subcontract production or sales off shore of their own product pending approval from FDA for domestic sales! This should add considerable revenue over the course of 1999 and IMO justifies a higher valuation for Gumm even without the cold remedy. Hoping to see $20 + in 1999 and if the cold remedy takes off during the next fall season we can expect a true rocket!